Bimatoprost (marketed in the US, Canada and Europe by Allergan, under the trade name Lumigan) ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. It binds to the prostanoid FP receptor. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation following ocular dosing. Bimatoprost then undergoes oxidation, N-deethylation and glucuronidation to form a diverse variety of metabolites. In human blood, bimatoprost resides mainly in the plasma. Approximately 12% of bimatoprost remains unbound in human plasma.

There is not information in the scientific papers related to the pharmacological and biological properties of bimatoprost acid methyl ester.

Bimatoprost acid is a metabolically stable analog of prostaglandin F2alpha, exhibits a relatively high affinity for the FP, EP1, and EP3 receptors and exhibits functional activity at the EP1 and FP receptors. Clinical pharmacological studies with bimatoprost reveal that it is not significantly metabolized due to the absence of free acid hydrolysis product in the systemic circulation after topical ocular administration to human volunteers. The hydrolysis of bimatoprost to a free acid occurs at very low rate.